Advancements in Radiomics for Immunotherapy of Non-small Cell Lung Cancer
Lung cancer is the main cause of cancer-related deaths,with non-small cell lung cancer(NSCLC)being the predominant subtype.At present,immunotherapy represented by immune checkpoint inhibitors(ICIs)of programmed cell death receptor 1 or its ligand has been widely used in the clinical diagnosis and treatment of patients with NSCLC.How-ever,only a few patients can benefit from it,and reliable predictive markers for immunotherapy are lacking.Radiomics is a tool that uses computer software and algorithms to extract a large amount of quantitative information from biomedical images.A large number of studies have confirmed that the radiomic model that predicts the immune efficacy of NSCLC can be used as a new type of immune efficacy predictive marker,which is expected to guide the individualized diagnosis and treatment deci-sions for patients with lung cancer and has a bright application prospect.This article reviews the research progress of radiomics in predicting the immune therapy response of NSCLC,identifying pseudo-progression and hyperprogression,ICIs-related pneumonia,cachexia risk,and combining with other genomics.
万方数据
维普
